In the news | 6th January 2014
Banking on biologics
American Laboratory
January 2014
Biologics means big bucks and big rewards. The pharma industry is keen to capitalize on this success as revenues are tipped to reach over $407 billion by 2018. By this time, more than 50% of the top 100 selling drugs will be biologics.
More news
Ensuring product, process and patient data integrity and traceability throughout the BioPharmaceutical lifecycle in the era of personalized medicine
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.